honeycomb shape

NGM Bio to Present Phase 2 Data of NGM282 in NASH at International Liver Congress 2017

April 5th 2017

SOUTH SAN FRANCISCO, CA, April 5, 2017 – NGM Bio, a research-driven biotechnology company that translates powerful biology into transformative medicines, today announced that new data from the company’s lead product candidate, NGM282, will be presented in oral and poster presentations at The International Liver Congress 2017, hosted by the European Association for the Study of the Liver (EASL) to be held April 19-23, 2017 in Amsterdam.

Dr. Stephen A. Harrison, M.D., Medical Director of Pinnacle Clinical Research and Visiting Professor of Hepatology at the Radcliffe Department of Medicine at the University of Oxford, UK, will present results from NGM Bio’s exploratory Phase 2 trial of NGM282 in nonalcoholic steatohepatitis (NASH) on Saturday, April 22nd at the oral late-breaker session. Patients with biopsy-confirmed NASH treated with NGM282 for 12 weeks showed rapid and highly significant reductions in magnetic resonance imaging (MRI) measures of liver fat content and serum biomarkers of liver function and fibrosis.

NGM Bio will also present a poster outlining the mechanism by which the human hormone FGF19 induces hepatocellular carcinoma in rodents, as well as in vitro and in vivo evidence that this signaling mechanism was engineered out of NGM282. A second poster will present nonclinical and clinical data demonstrating that NGM282-induced increases in serum LDL cholesterol were rapidly and completely mitigated by co-administration of a statin while maintaining the efficacy of NGM282.

Details on the oral and poster presentations are as follows:

Oral Presentation

Title: NGM282, a novel variant of FGF19, significantly reduces hepatic steatosis and key biomarkers of NASH: results of a Phase 2, multicenter, randomized, double-blinded, placebo controlled trial in biopsy-confirmed NASH patients
Late Breaker Session, Abstract LBO-07
Authors: S.A. Harrison, M.F. Abdelmalek, J.F. Trotter, A.H. Paredes, H.L. Arnold, M. Kugelmas, M.R. Bashir, L. Ling, S.J. Rossi, A.M. DePaoli, M.E. Rinella, R.S. Loomba
Date: Saturday, April 22, 2017
Time: 17:30 – 17:45 CEST
View Abstract (pdf)

Poster Presentations

Title: Activation of IL-6/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis
Session: Liver tumours: Experimental and pathophysiology, Abstract FRI-104
Authors: L. Ling, M. Zhou, H. Yang, R.M. Learned, S.J. Rossi, A.M. DePaoli, H. Tian
Date: Friday, April 21, 2017
Time: Guided poster tour with Professor Tom Lüedde, RWTH Aachen University, 11:00 – 11:30 CEST
View Abstract (pdf)

Title: Serum cholesterol changes associated with NGM282 treatment in obese insulin resistant cynomolgus monkeys are reversed with either a statin or a PCSK9 inhibitor
 Fatty liver disease: Experimental and pathophysiology, Abstract FRI-353
Authors: J. Luo, B. Ko, X. Ding, S.J. Rossi, A.M. DePaoli, H. Tian
Date: Friday, April 21, 2017
Time: Oral ePoster presentation by Jian Luo, Ph.D., NGM Bio at 12:30 – 13:30 CEST
View Abstract (pdf)

Additional information about the congress can be found on The International Liver Congress website.

About NGM282 in NASH

NGM282 is a non-tumorigenic, engineered variant of the human hormone FGF19 that dramatically reduces liver fat content and improves liver function by targeting multiple pathogenic pathways of nonalcoholic steatohepatitis (NASH). NGM has generated robust preclinical and early clinical evidence supporting NGM282’s ability to significantly improve steatosis, inflammation and fibrosis. This wholly-owned, single-agent therapeutic has the potential to resolve NASH rapidly, completely and across a broad spectrum of patients.

About NGM Biopharmaceuticals, Inc.

NGM Bio is a research-driven biotechnology company committed to discovering and developing novel biologics for the treatment of life-threatening diseases. NGM Bio’s portfolio consists of multiple programs in clinical testing and more than a dozen additional programs in various stages of preclinical development.  The company’s most advanced compound, NGM282, is a wholly-owned asset that has completed a Phase 2 trial in nonalcoholic steatohepatitis (NASH) and is being evaluated in a Phase 2 trial for the treatment of primary sclerosing cholangitis. NGM Bio has established a broad strategic collaboration with Merck. NGM Bio is backed by The Column Group, Merck, Prospect Ventures, Topspin Partners, Rho Ventures, Tichenor Ventures and other leading investors around the world. For more information, please visit www.ngmbio.com.


Jeff Jonker
NGM Biopharmaceuticals

Pam Lord
Canale Communications